Asset profile
Empagliflozin · Jardiance
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Chronic Kidney Disease, Type 2 Diabetes, Heart Failure
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atherosclerotic Cardiovascular Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
229 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 218 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Empagliflozin (Jardiance): this drug | Approved | Small molecule | SGLT2 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| DWP16001 (Enavogliflozin) | Phase 3 | Small molecule | SGLT2 | ||
| Janagliflozin | Phase 3 | Small molecule | SGLT2 | ||
| THR-1442 | Phase 3 | Small molecule | SGLT2 | ||
| DA-2811 | Phase 2 | Small molecule | SGLT2 | ||
| Tofogliflozin (Apleway / Deberza) | Phase 2 | Small molecule | SGLT2 | ||
| Rongliflozin | Phase 1 | Small molecule | SGLT2 | ||
| Zibotentan + Dapagliflozin | Phase 3 | Small molecule | Endothelin A receptor, SGLT2 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor |
…and 214 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Bexagliflozin · Type 2 Diabetesvs Canagliflozin · Type 2 Diabetes +1vs Dapagliflozin · Type 2 Diabetes +2vs Ertugliflozin · Type 2 Diabetesvs DWP16001 · Type 2 Diabetesvs janagliflozin · Type 2 Diabetes
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(81 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (19)
November 2026 (3)
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2026-11-01 · NCT06229678 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2026-11-30 · NCT05057806 · CT.gov ↗
What to watch
Phase 2/3Empagliflozin in Cardiorenal Syndrome Type 1Recruiting
Est. primary completion 2026-11-30 · NCT06030843 · CT.gov ↗
What to watch
December 2026 (16)
Phase 1Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2026-12 · NCT06554301 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12 · NCT07311551 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2026-12-01 · NCT07692256 · CT.gov ↗
What to watch
Phase 2Cirrhosis, Liver FailureRecruiting
Est. primary completion 2026-12-01 · NCT05726032 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-30 · NCT05786443 · CT.gov ↗
What to watch
Phase 2Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)Recruiting
Est. primary completion 2026-12-30 · NCT07336797 · CT.gov ↗
What to watch
Phase 4Lupus Nephritis (LN)Recruiting
Est. primary completion 2026-12-30 · NCT07700940 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT05392764 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT06531824 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT06055452 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06989723 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT05164263 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT05671991 · CT.gov ↗
What to watch
Phase 4Heart FailureActive not recruiting
Est. primary completion 2026-12-31 · NCT06260059 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12-31 · NCT06519448 · CT.gov ↗
What to watch
2027 (34)
January 2027 (1)
Phase 3Diabetes Type 1Recruiting
Est. primary completion 2027-01 · NCT06894784 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (3)
Phase 3Cardiogenic ShockRecruiting
Est. primary completion 2027-03-16 · NCT05879276 · CT.gov ↗
What to watch
Phase 2DMD-associated Dilated CardiomyopathyNot yet recruiting
Est. primary completion 2027-03-31 · NCT06643442 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-31 · NCT07442006 · CT.gov ↗
What to watch
April 2027 (3)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2027-04-30 · NCT07038356 · CT.gov ↗
What to watch
Early phase / not applicableHypertension (HTN)Not yet recruiting
Est. primary completion 2027-04-30 · NCT07678151 · CT.gov ↗
What to watch
May 2027 (4)
Phase 4Autosomal Dominant Polycystic KidneyActive not recruiting
Est. primary completion 2027-05 · NCT06391450 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-01 · NCT05715814 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2027-05-31 · NCT05138575 · CT.gov ↗
What to watch
Phase 2Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes MellitusRecruiting
Est. primary completion 2027-05-31 · NCT06729996 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT05960656 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053306 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053293 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053319 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT07292909 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-07 · NCT07155694 · CT.gov ↗
What to watch
August 2027 (4)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-08 · NCT07365358 · CT.gov ↗
What to watch
Phase 4Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionRecruiting
Est. primary completion 2027-08-01 · NCT07776054 · CT.gov ↗
What to watch
Phase 2Brugada Syndrome (BrS)Not yet recruiting
Est. primary completion 2027-08-21 · NCT07146880 · CT.gov ↗
What to watch
Early phase / not applicableCardiogenic ShockRecruiting
Est. primary completion 2027-08-31 · NCT07141355 · CT.gov ↗
What to watch
September 2027 (2)
November 2027 (1)
December 2027 (6)
Phase 3Congenital Heart DiseaseRecruiting
Est. primary completion 2027-12 · NCT06955260 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-12-01 · NCT06110130 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT06249932 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT06249945 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07771010 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver, Empagliflozin, SGLT2 InhibitorsActive not recruiting
Est. primary completion 2027-12-31 · NCT05147090 · CT.gov ↗
What to watch
2028 (14)
January 2028 (3)
Phase 2Non-Alcoholic Fatty Liver DiseaseRecruiting
Est. primary completion 2028-01-01 · NCT06355310 · CT.gov ↗
What to watch
Phase 2Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLDNot yet recruiting
Est. primary completion 2028-01-01 · NCT03867487 · CT.gov ↗
What to watch
Phase 3CardiotoxicityActive not recruiting
Est. primary completion 2028-01-01 · NCT05271162 · CT.gov ↗
What to watch
February 2028 (2)
April 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-04 · NCT07756294 · CT.gov ↗
What to watch
May 2028 (2)
September 2028 (1)
October 2028 (1)
Phase 2/3Aging, Arterial StiffnessRecruiting
Est. primary completion 2028-10-31 · NCT06506422 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Kidney StonesRecruiting
Est. primary completion 2028-11-01 · NCT07055282 · CT.gov ↗
What to watch
December 2028 (3)
Phase 4Partial Islet Function, TPIAT, DiabetesRecruiting
Est. primary completion 2028-12-01 · NCT07228195 · CT.gov ↗
What to watch
Phase 2Obesity, Vascular HealthRecruiting
Est. primary completion 2028-12-31 · NCT06745063 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT06642272 · CT.gov ↗
What to watch
2029 (9)
January 2029 (2)
February 2029 (2)
March 2029 (2)
August 2029 (1)
Phase 4Heart Transplant, Cardiovascular Disease, Kidney DiseaseRecruiting
Est. primary completion 2029-08-31 · NCT06625073 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaRecruiting
Est. primary completion 2029-10 · NCT07175051 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2029-12-14 · NCT07064473 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-03-31 · NCT06013865 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2030-07 · NCT06992440 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 3Coronary Microvascular Dysfunction (CMD)Not yet recruiting
Est. primary completion 2031-05 · NCT07533747 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.